<div id="readability-page-1"><div><figure></figure>Biopharmaceutical drug delivery company Halozyme Therapeutics will be announcing earnings results this Monday after market close. Here’s what to expect.Halozyme Therapeutics beat analysts’ revenue expectations last quarter, reporting revenues of $451.8 million, up 51.6% year on year. It was a softer quarter for the company, with a significant miss of analysts’ EPS estimates and a miss of analysts’ full-year EPS guidance estimates.Is Halozyme Therapeutics a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.This quarter, the market is expecting Halozyme Therapeutics’s revenue to grow 34.1% year on year, slowing from the 35.2% increase it recorded in the same quarter last year.<figure></figure>Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Halozyme Therapeutics rarely misses Wall Street’s revenue estimates.Looking at Halozyme Therapeutics’s peers in the therapeutics segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Novavax’s revenues decreased 79.1% year on year, beating analysts’ expectations by 96.3%, and Moderna reported revenues up 260%, topping estimates by 55.8%. Novavax traded up 17.4% following the results while Moderna was also up 3%.Read our full analysis of Novavax’s results here and Moderna’s results here.There has been positive sentiment among investors in the therapeutics segment, with share prices up 6.1% on average over the last month. Halozyme Therapeutics is down 5.3% during the same time and is heading into earnings with an average analyst price target of $85.78 (compared to the current share price of $64.22).ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.</div></div>

HALO

LABU

IBBQ

Halozyme Therapeutics will announce earnings results on Monday after market close. Last quarter, it reported revenues of $451.8 million, up 51.6% year on year, but missed EPS estimates. This quarter, revenue is expected to grow 34.1%. Analysts have reaffirmed estimates, indicating stability. Peers Novavax and Moderna have reported mixed results, with positive investor sentiment in the therapeutics segment. Halozyme's share price is down 5.3% recently, with an average analyst price target of $85.78 compared to its current price of $64.22.

Halozyme Therapeutics Earnings: What To Look For From HALO